Breaking: Promising Sonelokimab's HS Trial Data Propels MoonLake Immunotherapeutics
- June 26th, 2023
- 222 views
MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company, announced positive results from its Phase 2 MIRA trial, evaluating the effectiveness and safety of the Nanobody sonelokimab, administered subcutaneously, in patients with moderate-to-severe hidradenitis suppurativa (HS).
Hidradenitis suppurativa is a painful skin condition characterized by lumps that form in areas where skin touches skin.
The trial successfully met its primary endpoint, with a higher proportion of patients treated with sonelokimab achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 compared to those on placebo at week 12.
The results showed that sonelokimab exhibits strong clinical activity compared to other therapies evaluated in similar trials.
At present, $MLTX is trading at $47.59, representing a significant increase of $21.71 (+83.89%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Countdown: Lockheed Martin, Stryker, and PACCAR Gear Up
January 26th, 2025Earnings Spotlight: SoFi Technologies, Sanmina, and Nucor Set to Report
January 26th, 2025Global Flag Football League Plans To Host Pro Flag Football Tournament in Las Vegas
January 23rd, 2025Earnings On Deck: Netflix, United Airlines, and Agilysys Gear Up
January 19th, 2025
Member Login